Key result
Edoxaban is noninferior to warfarin for stroke and systemic embolism prevention (RR 0.65; 95% CI 0.23-1.81) and reduces cardiovascular mortality, but increases gastrointestinal bleeding.
Why the study?
Does edoxaban reduce stroke and systemic embolism compared to warfarin and other NOACs in adults with nonvalvular atrial fibrillation?
Population
Adults with nonvalvular atrial fibrillation (4 RCTs pooling 23,021 patients)
Comparison
Edoxaban vs Warfarin and other NOACs
Design
Systematic_review
Authors
Loading...
Edoxaban provides a practical option versus warfarin in nonvalvular AF; extends pooled RCT evidence while leaving head-to-head data versus other NOACs open.
Meta-Analysis (n=23,021)
Does edoxaban reduce stroke and systemic embolism compared to warfarin and other NOACs in adults with nonvalvular atrial fibrillation?
Relative Risk: 0.65 (95% CI 0.23–1.81)
Edoxaban is noninferior to warfarin for stroke prevention in nonvalvular atrial fibrillation and reduces cardiovascular mortality and major bleeding, though it increases the risk of gastrointestinal bleeding and anemia.
Aronow et al. (2018) conducted a meta-analysis in nonvalvular atrial fibrillation (n=23,021). Edoxaban vs. Warfarin was evaluated on stroke and systemic embolism (RR 0.65, 95% CI 0.23-1.81). Edoxaban is noninferior to warfarin for stroke and systemic embolism prevention (RR 0.65; 95% CI 0.23-1.81) and reduces cardiovascular mortality, but increases gastrointestinal bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: